concept

PD-L1

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about PD-L1: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

381Connections

0Hypotheses

0Analyses

50Outgoing

50Incoming

No summary available yet. View on Wiki →

💡 Concept Info

Name	PD-L1
Key Genes/Proteins	IL-6, PER2, PINK1, OMA1, PTPN1, STING1
Related Diseases	oral squamous cell carcinoma
Related Pathways	Jak2/Stat3 signaling, NF-κB

Wiki Pages (20)

Knowledge base pages for this entity

Pathway Diagram

graph TD
    PD_L1["PD-L1"]
    PD_L1 -->|"promotes"| IL_6["IL-6"]
    PD_L1 -->|"inhibits"| T_Cell_Activity["T Cell Activity"]
    PD_L1 -->|"activates"| Jak2_Stat3_signaling["Jak2/Stat3 signaling"]
    PD_L1 -->|"binds"| PD_1["PD-1"]
    PD_L1 -->|"inhibits"| T_cells["T cells"]
    PD_L1 -->|"promotes"| oral_squamous_cell_carcinoma["oral squamous cell carcinoma"]
    PD_L1 -->|"inhibits"| PTPN1["PTPN1"]
    PD_L1 -->|"inhibits"| T_cell_function["T-cell function"]
    PER2["PER2"] -->|"inhibits"| PD_L1
    PINK1["PINK1"] -->|"recruits_to_mitochondria"| PD_L1
    OMA1["OMA1"] -->|"upregulates"| PD_L1
    PD_1 -->|"inhibits"| PD_L1
    TCe6_Cu_TP5_NPs["TCe6@Cu/TP5 NPs"] -->|"downregulates"| PD_L1
    NF__B["NF-kappaB"] -->|"activates"| PD_L1
    SMARCAL1["SMARCAL1"] -->|"promotes"| PD_L1
    Atezolizumab["Atezolizumab"] -->|"targets"| PD_L1

Outgoing (226)

Target	Relation	Type	Str
IL-6	promotes	protein	0.95
T Cell Activity	inhibits	process	0.95
Jak2/Stat3 signaling	activates	pathway	0.93
T cells	inhibits	cell_type	0.90
oral squamous cell carcinoma	promotes	disease	0.90
PTPN1	inhibits	protein	0.90
T-cell function	inhibits	process	0.90
Immunotherapy	regulates	process	0.90
STAT3	binds_to	protein	0.89
Cancer Cell Proliferation	involved_in	process	0.85
T Cell Cytotoxicity	inhibits	process	0.85
Systemic Immune Suppression	mediates	process	0.80
Cancer	inhibits	disease	0.65
ALS	inhibits	disease	0.65
Carcinoma	inhibits	disease	0.65
ALS	activates	disease	0.65
Tumor	inhibits	disease	0.65
Tumor	activates	disease	0.65
Cancer	activates	disease	0.65
Carcinoma	activates	disease	0.65
Glioblastoma	activates	disease	0.65
Als	therapeutic_target	disease	0.65
Cancer	therapeutic_target	disease	0.65
Als	activates	disease	0.65
Glioblastoma	therapeutic_target	disease	0.65
Als	expressed_in	disease	0.65
Cancer	biomarker_for	disease	0.65
Glioblastoma	inhibits	disease	0.65
Cancer	associated_with	disease	0.65
Tumor	expressed_in	disease	0.65
ALS	expressed_in	disease	0.65
Carcinoma	biomarker_for	disease	0.65
Tumor	degrades	disease	0.65
Cancer	degrades	disease	0.65
Inflammation	activates	disease	0.65
Multiple Sclerosis	expressed_in	disease	0.65
Aging	therapeutic_target	disease	0.65
WNT	inhibits	gene	0.60
LZTR1	inhibits	gene	0.60
SF3B1	inhibits	gene	0.60
APOB	inhibits	gene	0.60
EEF1A1	inhibits	gene	0.60
P53	inhibits	gene	0.60
RNA	inhibits	gene	0.60
MDM4	inhibits	gene	0.60
SMARCA4	inhibits	gene	0.60
TERT	inhibits	gene	0.60
JUN	inhibits	gene	0.60
AND	inhibits	gene	0.60
CANCER	inhibits	gene	0.60

Incoming (155)

Source	Relation	Type	Str
PER2	inhibits	gene	0.95
PINK1	recruits_to_mitochondria	protein	0.95
OMA1	upregulates	protein	0.95
PD-1	inhibits	gene	0.95
STING1	associated_with	protein	0.90
type I interferon	associated_with	protein	0.90
TCe6@Cu/TP5 NPs	downregulates	compound	0.90
NF-κB	activates	pathway	0.90
SMARCAL1	promotes	gene	0.90
Atezolizumab	targets	drug	0.90
Durvalumab	targets	drug	0.90
Avelumab	targets	drug	0.90
cGAS-STING Pathway	upregulates	pathway	0.90
JUN	interacts_with	protein	0.85
NUPR1	upregulates	gene	0.85
brain metastases	associated_with	disease	0.70
PD-1	activates	gene	0.65
LYSOSOME	activates	gene	0.60
AND	inhibits	gene	0.60
CD8	activates	gene	0.60
CCL2	inhibits	gene	0.60
GBM	activates	gene	0.60
LYSOSOME	inhibits	gene	0.60
SQSTM1	inhibits	gene	0.60
MCL1	therapeutic_target	gene	0.60
MDM4	therapeutic_target	gene	0.60
LZTR1	therapeutic_target	gene	0.60
VEGFA	therapeutic_target	gene	0.60
WNT	therapeutic_target	gene	0.60
DNA	therapeutic_target	gene	0.60
IGF2R	therapeutic_target	gene	0.60
EOMES	activates	gene	0.60
GBM	therapeutic_target	gene	0.60
ROS	therapeutic_target	gene	0.60
DES	biomarker_for	gene	0.60
DNA	biomarker_for	gene	0.60
MITOPHAGY	activates	gene	0.60
OMA1	activates	gene	0.60
HSPA9	therapeutic_target	gene	0.60
DNA	activates	gene	0.60
HER2	activates	gene	0.60
APOPTOSIS	activates	gene	0.60
SCD1	activates	gene	0.60
HMGCR	activates	gene	0.60
IBA1	expressed_in	gene	0.60
GBM	inhibits	gene	0.60
TMEM119	expressed_in	gene	0.60
IFN	associated_with	gene	0.60
CDKN2A	expressed_in	gene	0.60
MAP2K2	expressed_in	gene	0.60

Targeting Hypotheses (0)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
No targeting hypotheses

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

PD-L1

Understanding Entity Pages

Wiki Pages (20)

Microglia CD8+ T Cell Recruitment -- Supplementary WW Content

N-of-1 and Personalized Clinical Trial Design for CBS/PSP

PD-1/PD-L1 Immune Checkpoint Signaling in Neurodegeneration

Peptidream Inc.

eef1a1

Innovent Biologics

MAP2K2 Gene

myasthenia-gravis

Neuroimmune Checkpoint-Metal-Oxidative Stress Convergence Synthesis

AD Neuroimmune Checkpoint and TREM2 Pathway Companies

immunotherapy-update

MK-6837 Phase 1 Solid Tumor Trial (NCT06460961)

CD200 Gene

T-Cell Dysfunction in Neurodegeneration

STAT5B Gene

CD3G Gene

il29

Neuroimmune Checkpoint Dysfunction in Neurodegeneration